BlueRock Therapeutics Nachrichten und Aktivitäten
Führungskräfte
Siehe das Organigramm mit seine 18 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei BlueRock Therapeutics
- Seth Ettenberg, Director, President and Chief Executive Officer
- Doug Kerr, Director
- Juergen Eckardt, Director
Letzte Veränderungen der Führungskräfte auf BlueRock Therapeutics
- Rebecca Kauffman Milbury der/die zuvor Senior Vice President, Head of People and Culture war, wurde zum Chief People Officer befördert (Nachrichten veröffentlicht am 17, Februar 2025).
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von BlueRock Therapeutics nachzuverfolgen.
Biotechnologie
BlueRock Therapeutics hat 2.350 Konkurrenten , einschließlich Astellas Gene Therapies (USA), Eurofins (Luxemburg) und Lonza (Schweiz).
Popular M&A news in Biotechnologie
- Sirius Therapeutics hat gerade eine Spendenaktion von 50 Millionen Dollar angekündigt. (veröffentlicht am 16, Juni 2025).
- BioNTech has announced the acquisition of CureVac (veröffentlicht am 12, Juni 2025).
- SpliceBio hat gerade eine Spendenaktion von 135 Millionen Dollar angekündigt. (veröffentlicht am 11, Juni 2025).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach BlueRock Therapeutics
- News - BlueRock Therapeutics LP
- BlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell TherapyBlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell Therapy
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Diseas
- BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced
- Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine - Engineered Cell TherapySenti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Th
- BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases - Engineered Cell TherapyBlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis The
- BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell Therapy
- BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease - Engineered Cell Therapy
- BlueRock Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
- BlueRock Therapeutics President and CEO Emile Nuwaysir elected to serve as Vice Chairman of the Alliance for Regenerative Medicine
- View more press releases Close
Social media about BlueRock Therapeutics
- BlueRock Therapeutics auf Wikipedia, Google News & Yahoo Finance
- BlueRock Therapeutics auf LinkedIn, Twitter & YouTube
